


STAR+PLUS Pilot Program

Evaluation Protocol Updates November 2022

Khairul Siddiqi, PhD Bruce Vogel, PhD Irina Bondoc, MS Institute for Child Health Policy University of Florida, College of Medicine





- <u>Evaluation Objective 1.</u> Assess the effect of the pilot program on access, quality, personcenteredness, and cost-effectiveness of Long-Term Services & Supports (LTSS) provided to STAR+PLUS members. Specific aims to assess:
 - (1a) Access/quality of LTSS
 - (1b) Informed choice, person-centered planning, flexible CDS, individualized budgeting, self-determination,
 community integration
 - (1c) Service integration
 - (1d) Employment assistance and options
 - (1e) Fair hearings and appeals
 - (1f) Use of and flexible consumer directed services (CDS)
 - (1g) Alternatives to guardianship
 - o (1h) Cost-effectiveness
 - o (1i) Attendant recruitment and retention



- <u>Evaluation Objective 2.</u> Analyze the experiences and outcomes of systems changes that will occur following implementation of the pilot program. Specific aims to assess:
 - (2a) Comprehensive assessment instrument (interRAI ID)
 - (2b) 21st Century Cures Act (systems for EVV)
 - (2c) CMS HCBS Settings rules for person-centered planning, person-centered plans, and HCBS settings
 - o (2d) Attendant and habilitation service provision
 - (2e) Managed care benefits



- <u>Evaluation Objective 3.</u> Elicit feedback on the pilot program based on the personal experiences of pilot program participants, their families, and their comprehensive LTSS providers. Specific aims to collect feedback from:
 - o (3a) Members- Individuals with IDD or similar functional needs
 - o (3b) Families- persons actively involved in the lives of individuals with IDD
 - o (3c) Comprehensive LTSS providers- who delivered services under the pilot program

Study design

- **Treatment group:** STAR+PLUS members who live in the pilot service area, meet the eligibility criteria for inclusion in the pilot, and are enrolled in a pilot MCO
- **Comparison group 1:** STAR+PLUS members who live in the pilot service area and meet the eligibility criteria for inclusion in the pilot, but are enrolled in a non-pilot MCO (or select MCO from another service area)
- **Comparison group 2:** STAR+PLUS members who live in the pilot service area and are enrolled in an IDD waiver




Figure 1. STAR+PLUS Pilot Program Evaluation Study Populations




Data Sources

- Structured surveys/interviews with pilot program participants and their families: NCI-IPS (videoconference or in-person), NCI-AFS (mail or web)
- Case management records, including assessment forms and individual service plans (ISPs)
- Administrative data, including enrollment, claims and encounter data
- Qualitative interviews and focus groups

Measures

- National Core Indicators In-Person Survey
- National Core Indicators Adult Family Survey
- CMS MLTSS measures for comprehensive assessment and care plans
- HEDIS, CAHPS, 3M potentially preventable events
- Measures developed by ICHP





Cost-effectiveness analysis



Aim 1h: Best and most cost-effective use of funding


- Cost-effectiveness: The degree to which the pilot program decreases the costs and/or improves the outcomes for treatment group participants relative to the participants in the comparison groups.
- Cost-effectiveness will be described using the incremental cost-effectiveness ratio (ICER),
 which is the ratio of the incremental cost of care to the incremental effectiveness of care.
- Effectiveness will be described using Quality-Adjusted Life Years (QALYs), which will be measured through the EQ-5D module (mobility, self-care, usual activity, pain/discomfort, anxiety/depression) added to the NCI-IPS.
- QALY: 1= one year of life spent in perfect health, 0=death.




• The formula for the Incremental Cost Effectiveness Ratio (ICER) is:


$$ICER = \frac{Incremental\ Cost}{Incremental\ QALYs} = \frac{Cost\ _{treatment} - Cost_{comparison}}{QALYs_{treatment} - QALYs_{comparison}}$$

 Budget impact analysis will assess costs solely from the payor perspective of the Texas Medicaid program.



Inverse Propensity Score Weighting (IPSW) to include IDD waiver members





$$\ln \frac{P}{1-P} = \beta_0 + \beta_1 Demographics + \beta_2 Eligibility\ Groups + \beta_3 Chronic\ Conditions +$$

$$\beta_4 Comorbidities + \varepsilon_P$$

 The second and final step in IPSW estimation involves estimating the outcomes model after weighting each enrollee's observation by the inverse of that enrollee's predicted propensity score:

LTSS Outcome =
$$\gamma_0 + \gamma_1 Demographics + \gamma_2 Eligibility Groups + \gamma_3 Chronic Conditions + \gamma_4 Comorbidities + \gamma_5 Treatment + \varepsilon_0$$





Service coordination records review

- August 2022: Ad hoc study to assess whether state and MCO case management forms, such as functional assessment and service planning forms are designed in a way that allows calculation of the CMS MLTSS measures.
- November 2022: Meet with data team for methodology to establish transmission of completed forms.
- December 2022 April 2023: Case management forms completeness/ quality review study.
- May 2023: Results from case management forms completeness/quality review study included in Quarterly progress/monitoring report to HHSC (#3).



National Core Indicators In-Person Survey (NCI IPS)

- A total of 1,200 surveys, 400 in each group, will be conducted for:
 - (1) Treatment group: STAR+PLUS members in the SP3 program
 - o (2) Comparison group 1: STAR+PLUS members in the non-pilot MCOs
 - (3) Comparison group 2: STAR+PLUS members in the IDD waiver programs.

 Primary data collection will occur once during the pre-pilot period (June -November 2023) and once during the first year of the pilot period (June – November 2024).



Discussion

